Impact of novel agents followed by autologous hematopoietic stem cell transplantation for multiple myeloma patients aged 65 years or older: a retrospective single Institutional analysis

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 50; no. 11; p. 1486
Main Authors Minoia, C, Pisapia, G, Palazzo, G, Ingrosso, C, Buonanno, M, Spinosa, C, Prudenzano, A, Pricolo, G, Mazza, P
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.11.2015
Subjects
Aged
Angiogenesis Inhibitors - administration & dosage
Angiogenesis Inhibitors - therapeutic use
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Bone marrow
Bortezomib
Bortezomib - administration & dosage
Bortezomib - therapeutic use
Cyclophosphamide - pharmacology
Drug therapy
Elderly patients
Female
Filgrastim
Granulocyte Colony-Stimulating Factor - pharmacology
Hematopoietic Stem Cell Mobilization
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cells
Humans
Interferon-alpha - administration & dosage
Male
Multiple myeloma
Multiple Myeloma - drug therapy
Multiple Myeloma - therapy
Patient outcomes
Physiological aspects
Polyethylene Glycols
Proteasome Inhibitors - administration & dosage
Proteasome Inhibitors - therapeutic use
Recombinant Proteins - pharmacology
Remission Induction
Retrospective Studies
Stem cell transplantation
Stem cells
Thalidomide - administration & dosage
Thalidomide - therapeutic use
Transplantation
Transplantation Conditioning
Transplantation, Autologous
Treatment Outcome
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-1
content type line 63
ObjectType-Correspondence-2
ISSN:0268-3369
1476-5365
DOI:10.1038/bmt.2015.185